Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia.
about
Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristineRecent advances and novel treatment paradigms in acute lymphocytic leukemiaTreating adults with acute lymphocytic leukemia: new pharmacotherapy options.SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemiaClofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia.Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia.Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemiasGenetic and epigenetic variants contributing to clofarabine cytotoxicity.High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.Novel targeted therapies in acute lymphoblastic leukemia.Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia.Clofarabine for the treatment of adult acute lymphoid leukemia: the Group for Research on Adult Acute Lymphoblastic Leukemia intergroup.Philadelphia chromosome-negative acute lymphoblastic leukemia: therapies under development.Modern immunotherapy of adult B-lineage acute lymphoblastic leukemia with monoclonal antibodies and chimeric antigen receptor modified T cells.Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia.Healthcare burden and reimbursement of hospitalization during chemotherapy for adults with Ph-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia in France: a retrospective chart review.Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults.Decitabine as a conditioning regimen in haploidentical stem cell transplantation for refractory acute myeloid leukaemia.Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?Isolation and characterization of a murine P388 leukemia line resistant to clofarabine.A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee).Pharmacogenomic Discovery Delineating the Genetic Basis of Drug Response.Histone H4 acetylation by immunohistochemistry and prognosis in relapsed acute lymphocytic leukaemia (ALL).Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia.Comparable Outcomes of Patients Eligible versus Ineligible for SWOG Leukemia Studies.
P2860
Q27000078-E9FC9BE3-C64F-4A06-ABA5-E2B6E28700A5Q28078076-CEDFDA23-EBFC-4ED6-AF2C-4DD908BBBC55Q30243925-DAC6B63F-431A-424B-A786-63BC7A672262Q34404280-A6B7C2B2-7D0E-4CAE-9EFF-9CE0F6B8CD26Q35278018-5AF2FA53-C995-4493-A3BF-522E271B7169Q35740894-DF4DFDC0-483F-46C7-80F6-B85C9B6DD62AQ36075766-1A9C1829-69F5-4C45-BB9B-B7A1B842F6EEQ37153800-5407C6A8-0F6E-4C5C-9702-E1DEAF167727Q37163738-9C645A1A-F6F7-4298-BE89-B751D222D1C2Q38120551-1223E17D-52B4-4671-B3D4-28E3AE20D3F9Q38164108-DC9B6EC0-162A-4595-9177-6948F26D325DQ38226402-2FE2F5B6-9D8D-4BB5-A9E0-2DD91A7D68F6Q38282458-E5361D3F-5725-4984-ADB7-837CE1C9A675Q38312596-5E346E98-29B6-4FF6-A95E-873894CBBA06Q38527924-8B6F35FE-5F0D-4061-8A35-D3231D317813Q38840247-49D4836F-3A48-46AC-B8FD-B6176AEDD5D6Q38840423-46F1853E-0DCA-4948-8E41-290F88470EFDQ39023384-6D53466D-DD9C-4ADD-AAA1-C12972922EA3Q39380445-75494BBA-E00A-4E4F-A644-A8AB20415C1CQ39446984-1A2A791C-975E-4D7E-9224-DA30D574EB65Q40996804-86AF4210-64BD-4591-8EC1-F1A13337E01EQ42586040-A10626EA-0089-4F0D-BF5B-553089A58CEAQ45968877-73A22396-CC28-4D70-A6CD-27F29B2F9A80Q48192887-9F4D7304-A220-4075-8354-B9287CADA216Q53832560-9A7EC197-6CEE-4F95-B1D8-3A5BD05CE17F
P2860
Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Southwest Oncology Group Study ...... y acute lymphocytic leukaemia.
@ast
Southwest Oncology Group Study ...... y acute lymphocytic leukaemia.
@en
Southwest Oncology Group Study ...... y acute lymphocytic leukaemia.
@nl
type
label
Southwest Oncology Group Study ...... y acute lymphocytic leukaemia.
@ast
Southwest Oncology Group Study ...... y acute lymphocytic leukaemia.
@en
Southwest Oncology Group Study ...... y acute lymphocytic leukaemia.
@nl
prefLabel
Southwest Oncology Group Study ...... y acute lymphocytic leukaemia.
@ast
Southwest Oncology Group Study ...... y acute lymphocytic leukaemia.
@en
Southwest Oncology Group Study ...... y acute lymphocytic leukaemia.
@nl
P2093
P2860
P921
P1476
Southwest Oncology Group Study ...... y acute lymphocytic leukaemia.
@en
P2093
Anjali S Advani
Holly M Gundacker
Jeffrey E Lancet
Jerald P Radich
Marilyn L Slovak
Martha P Mims
Olga Sala-Torra
Patrick J Stiff
Raymond Lai
Steve E Coutre
P2860
P304
P356
10.1111/J.1365-2141.2010.08387.X
P407
P577
2010-12-01T00:00:00Z